US Stock MarketDetailed Quotes
ADVM Adverum Biotechnologies
- 6.9400
- +0.3300+4.99%
Close Sep 27 16:00 ET
- 6.9400
- 0.00000.00%
Post 16:02 ET
144.36MMarket Cap-879P/E (TTM)
7.0800High6.6600Low108.79KVolume6.7300Open6.6100Pre Close755.95KTurnover0.79%Turnover RatioLossP/E (Static)20.80MShares29.700052wk High0.86P/B95.06MFloat Cap6.380052wk Low--Dividend TTM13.70MShs Float624.8000Historical High--Div YieldTTM6.35%Amplitude5.3100Historical Low6.9480Avg Price1Lot Size
Adverum Biotechnologies Stock Forum
Sign in to post a comment
$Adverum Biotechnologies (ADVM.US)$ Reuters· just
Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet AMD
Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet AMD
1
$Adverum Biotechnologies (ADVM.US)$
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...
2
$Adverum Biotechnologies (ADVM.US)$
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
$Adverum Biotechnologies (ADVM.US)$ Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
1
2
$Adverum Biotechnologies (ADVM.US)$ 2 insiders buy 200k cash in private placement, settlement Feb 8 the data release day. Lol, simple insider trading. Are they stupid? Anyway, there won’t be surprise for the data release, should be safe pass.
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
1
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Let’s see.
$Adverum Biotechnologies (ADVM.US)$Adverum Biotechnologies Has Agreed To Sell Approximately 106.25M Shares In A Private Placement At $1.20/Share With Gross Proceeds Of Approximately $127.5M; Pro Forma Cash And Investments Expected To Fund Current Operating Plan Into Late 2025
1
$Adverum Biotechnologies (ADVM.US)$ 2 dollars?
2
3
Yes!!!
Who is the winner today, after the poditive data announced on 03 Feb
$EyePoint Pharmaceuticals (EYPT.US)$
$Adverum Biotechnologies (ADVM.US)$
$Regenxbio (RGNX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Kodiak Sciences (KOD.US)$
$EyePoint Pharmaceuticals (EYPT.US)$
$Adverum Biotechnologies (ADVM.US)$
$Regenxbio (RGNX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Kodiak Sciences (KOD.US)$
1
$Adverum Biotechnologies (ADVM.US)$ I’ll probably sell most position at $2. I feels like phase 2 is great, and they are working with some IB to do stock offering once news is out.
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
QMengColdJoke : I am buying back, this designation itself means nothing but in the end will make final approval easier and faster.